2023
Spectrum of Dermatologic Adverse Events Associated With Amivantamab Use
Belzer A, Nguyen M, Talsania A, Haldas J, Smith J, Leventhal J. Spectrum of Dermatologic Adverse Events Associated With Amivantamab Use. JAMA Dermatology 2023, 159: 109-111. PMID: 36416832, PMCID: PMC9685543, DOI: 10.1001/jamadermatol.2022.4466.Peer-Reviewed Original Research
2022
Psoriasiform and lichenoid eruptions as a potential harbinger of bullous dermatoses in the setting of immune checkpoint inhibitors: a case series
Ahearn EL, Belzer A, Cohen SR, Leventhal JS, Deverapalli SC. Psoriasiform and lichenoid eruptions as a potential harbinger of bullous dermatoses in the setting of immune checkpoint inhibitors: a case series. International Journal Of Dermatology 2022, 62: e411-e414. PMID: 36271737, DOI: 10.1111/ijd.16464.Peer-Reviewed Original Research
2020
Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series
Ligtenberg KG, Hu JK, Damsky W, Olino K, Kluger H, Clune J, Cowper SE, Panse G, Leventhal J, Weiss SA. Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series. JAAD Case Reports 2020, 6: 628-633. PMID: 32613057, PMCID: PMC7317689, DOI: 10.1016/j.jdcr.2020.05.010.Peer-Reviewed Case Reports and Technical Notes
2015
100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series
Shi VY, Tran K, Patel F, Leventhal J, Konia T, Fung MA, Wilken R, Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series. Journal Of The American Academy Of Dermatology 2015, 73: 645-654. PMID: 26259990, DOI: 10.1016/j.jaad.2015.06.060.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, TopicalAminoquinolinesCohort StudiesDrug Therapy, CombinationFemaleFollow-Up StudiesHumansImiquimodInjections, IntralesionalInterleukin-2MaleMelanomaNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingRetinoidsRetrospective StudiesRisk AssessmentSkin NeoplasmsTreatment OutcomeConceptsIntralesional IL-2Cutaneous melanoma metastasesCutaneous metastatic melanomaIL-2Topical imiquimodMetastatic melanomaMelanoma metastasesCase seriesUS National Comprehensive Cancer Network guidelinesCommon treatment-related adverse eventsResponse rateNational Comprehensive Cancer Network guidelinesTreatment-related adverse eventsComplete response rateRetrospective case seriesPromising therapeutic optionLocal response rateAdverse eventsRetrospective reviewSurgical excisionNetwork guidelinesTherapeutic optionsCombination therapyBiopsy specimensRetinoid cream